Edition:
United States

Recordati Industria Chimica e Farmaceutica SpA (RECI.MI)

RECI.MI on Milan Stock Exchange

35.51EUR
21 Jul 2017
Change (% chg)

€-0.97 (-2.66%)
Prev Close
€36.48
Open
€36.35
Day's High
€36.66
Day's Low
€35.51
Volume
358,955
Avg. Vol
634,183
52-wk High
€38.01
52-wk Low
€24.55

Select another date:

Wed, Jul 19 2017

BRIEF-Recordati: European Commission approves Reagila as schizophrenia treatment

* EUROPEAN COMMISSION APPROVES REAGILA (CARIPRAZINE) FOR TREATMENT OF SCHIZOPHRENIA Source text: http://bit.ly/2teBSwQ Further company coverage: (Gdynia Newsroom)

BRIEF-Recordati signs exclusive license agreement with MimeTech

June 16 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA:

AstraZeneca sells aging beta-blocker to Recordati for $300 million

LONDON AstraZeneca has sold the European rights to its aging beta-blocker heart drug Seloken to Italy's Recordati for $300 million, as part of a continuing drive by the British drugmaker to spin off non-core assets.

BRIEF-Recordati Rare Diseases buys North American marketing rights to Cystadane

April 13 Recordati Industria Chimica e Farmaceutica SpA:

BRIEF-Recordati incorporates unit Recordati SA Chemical and Pharmaceutical Company

March 2 Recordati Industria Chimica e Farmaceutica SpA:

BRIEF-Italy's Recordati sees 2019 sales at around 1.45 bln euros

* sees 2019 sales at around 1.45 billion euros Source text for Eikon: Further company coverage: (Reporting by Milan newsroom)

Select another date: